Pharma BD Deal Intelligence
GSK acquired clinical-stage Affinivax for $2.1B cash upfront plus up to $1.2B in development milestones (up to ~$3.3B total), closing 23 Aug 2022, to obtain the Multiple Antigen Presenting System (MAPS) vaccine platform and lead candidate AFX3772, a 24-valent pneumococcal vaccine, as a challenge to Pfizer's Prevnar franchise. On its Q3 2024 update (30 Oct 2024) GSK discontinued the 24-valent adult program (AFX3772), citing increased competition, and pivoted to a preclinical 30-plus-valent MAPS successor targeted to enter the clinic in 2025; a 24-valent pediatric program continued in Phase 2. The platform bet on MAPS remains in development; the originally acquired lead asset has been superseded.